- Home
- BHLB vs SNDX Comparison
BHLB vs SNDX Comparison
Compare BHLB & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHLB
- SNDX
- Stock Information
- Founded
- BHLB 1846
- SNDX 2005
- Country
- BHLB United States
- SNDX United States
- Employees
- BHLB N/A
- SNDX N/A
- Industry
- BHLB Banks
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BHLB Finance
- SNDX Health Care
- Exchange
- BHLB Nasdaq
- SNDX Nasdaq
- Market Cap
- BHLB 1.1B
- SNDX 1.1B
- IPO Year
- BHLB 2000
- SNDX 2016
- Fundamental
- Price
- BHLB $26.32
- SNDX $9.60
- Analyst Decision
- BHLB Hold
- SNDX Strong Buy
- Analyst Count
- BHLB 5
- SNDX 11
- Target Price
- BHLB $32.70
- SNDX $34.18
- AVG Volume (30 Days)
- BHLB 516.3K
- SNDX 2.0M
- Earning Date
- BHLB 07-24-2025
- SNDX 07-31-2025
- Dividend Yield
- BHLB 2.75%
- SNDX N/A
- EPS Growth
- BHLB 392.17
- SNDX N/A
- EPS
- BHLB 2.46
- SNDX N/A
- Revenue
- BHLB $431,403,000.00
- SNDX $43,722,000.00
- Revenue This Year
- BHLB $31.27
- SNDX $426.77
- Revenue Next Year
- BHLB $78.77
- SNDX $98.31
- P/E Ratio
- BHLB $10.64
- SNDX N/A
- Revenue Growth
- BHLB 33.05
- SNDX N/A
- 52 Week Low
- BHLB $22.27
- SNDX $8.58
- 52 Week High
- BHLB $32.36
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- BHLB 58.05
- SNDX 48.99
- Support Level
- BHLB $26.28
- SNDX $8.59
- Resistance Level
- BHLB $26.96
- SNDX $10.01
- Average True Range (ATR)
- BHLB 0.59
- SNDX 0.54
- MACD
- BHLB 0.16
- SNDX 0.10
- Stochastic Oscillator
- BHLB 76.64
- SNDX 71.48
About BHLB Berkshire Hills Bancorp Inc.
Berkshire Hills Bancorp Inc is a holding company. It provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.